search
Back to results

Probiotics and the Neurodevelopment in the Premature Infant <32 Weeks Gestational Age and <1500g

Primary Purpose

Infant, Newborn, Diseases, Infant Development

Status
Active
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748
Sponsored by
Fundacion Clinic per a la Recerca Biomédica
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infant, Newborn, Diseases focused on measuring Probiotics, Bifidobacterium bifidum, Lactobacillus acidophilus, Neurodevelopment, Prematurity, Late-onset sepsis

Eligibility Criteria

undefined - 32 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Premature infants under 32 weeks gestational age and less than 1500g birthweight. Born at BCNatal Hospital Clínic between years 2014-2019. Exclusion Criteria: All neonates presenting with suspected congenital anomalies, inborn errors of metabolism, or genetic defects were excluded. Infants with a suspected syndrome, or who have suffered events beyond the neonatal period, not related to prematurity, that could entail impairment in neurodevelopment (severe cranioencephalic trauma, oncological process, meningitis, or exposure to toxic substances)

Sites / Locations

  • Neonataology Service, BCNatal Hospital Clinic Seu Maternitat

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748

Control

Arm Description

Daily dose of 6x109 UFC Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) from 7 days of life until reaching a postmenstrual age of 34 weeks or discharge

Untreated control group

Outcomes

Primary Outcome Measures

Degree of neurodevelopment at 24 months corrected age
Normal neurodevelopment will be considered when no muscle tone changes, no impaired fine or gross motor coordination, Bayley scale score between above 84, no behaviour disorders or visual disability.
Degree of neurodevelopment at 24 months corrected age
Mild impairment will be considered if any of the following: muscle tone changes, impaired fine or gross motor coordination, Bayley scale score between 71-84, moderate behaviour disorders or mild visual disability.
Degree of neurodevelopment at 24 months corrected age
Moderate impairment will be diagnosed when suffering from any of the following: spastic diplegia, hemiplegia, seizures (non-febrile), Bayley scores between 50-70, severe behaviour disorders, moderate visual disability or mild-moderate hypoacusis.
Degree of neurodevelopment at 24 months corrected age
Severe impairment will be attributed to subjects with any of the following: spastic quadriplegia, choreoathetosis, ataxia, Bayley score <50, blindness or severe hypoacusis
Degree of neurodevelopment at 6 years of age
Wechsler Intelligence Scale for Children - Fifth edition. Ranges from below 69 to above 130. Scores from 90-109 indicate average, above it indicates above average and below, below average performance.
Degree of neurodevelopment at 6 years of age
Child behaviour checklist 6-18 years of age. 113 items about behaviour and social competence scored from 0 "absent" to 2 "occurs often"
Degree of neurodevelopment at 6 years of age
Behavior Rating Inventory of Executive Function, Second Edition (BRIEF2). Parent/teacher self reporting form.
Neuroplasticity biomarkers and intestinal permeability
NeuN, Doublecortin, GFAP, GDNF, Ki67, Nrf2, BDNF, NGF, neurotrophin-1 (NT-1), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), DYRK1A, HIF1α, S100B i GSK3B. IL1B, IL6, IL8, IL10, IL12, TNF- α

Secondary Outcome Measures

Incidence of necrotising enterocolitis
cases fulfilling the stage II or above of the modified Bell's Criteria
Mortality
Proportion of dead participants before discharge
Incidence of late onset sepsis
positive blood culture beyond 72 hours of life
Incidence of Intraventricular haemorrhage
Grade I-IV
Intensive care length of stay
Days of intensive care

Full Information

First Posted
May 19, 2023
Last Updated
August 10, 2023
Sponsor
Fundacion Clinic per a la Recerca Biomédica
Collaborators
Hospital Clinic of Barcelona
search

1. Study Identification

Unique Protocol Identification Number
NCT05945017
Brief Title
Probiotics and the Neurodevelopment in the Premature Infant <32 Weeks Gestational Age and <1500g
Official Title
Probiotics and the Neurodevelopment in the Premature Infant <32 Weeks Gestational Age and <1500g
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 1, 2014 (Actual)
Primary Completion Date
December 31, 2019 (Actual)
Study Completion Date
December 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundacion Clinic per a la Recerca Biomédica
Collaborators
Hospital Clinic of Barcelona

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Unicentric, quasi-experimental, cohort study to evaluate the effect of combining two probiotics (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) in the neurodevelopment of preterm neonates below 32 weeks' gestation and a birthweight under 1,500 g. This probiotic combination has shown to be safe and beneficial in premature neonates in the prevention of NEC. The investigators hypothesised that this mixture would contribute to better neurodevelopmental outcomes of preterm neonates when assessed at 24 months corrected age. Additionally, neurodevelopment improved would be more relevant at 6 years of age, together with a better pattern of neuronal plasticity biomarkers. Secondarily, this mixture of probiotics could reduce NEC, LOS, intraventricular haemorrhage and neonatal mortality in accordance with previous studies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infant, Newborn, Diseases, Infant Development
Keywords
Probiotics, Bifidobacterium bifidum, Lactobacillus acidophilus, Neurodevelopment, Prematurity, Late-onset sepsis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Sequential study with consecutive recruitment with a washout period of 12 months between groups
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
233 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748
Arm Type
Experimental
Arm Description
Daily dose of 6x109 UFC Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) from 7 days of life until reaching a postmenstrual age of 34 weeks or discharge
Arm Title
Control
Arm Type
No Intervention
Arm Description
Untreated control group
Intervention Type
Dietary Supplement
Intervention Name(s)
Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748
Primary Outcome Measure Information:
Title
Degree of neurodevelopment at 24 months corrected age
Description
Normal neurodevelopment will be considered when no muscle tone changes, no impaired fine or gross motor coordination, Bayley scale score between above 84, no behaviour disorders or visual disability.
Time Frame
24 months
Title
Degree of neurodevelopment at 24 months corrected age
Description
Mild impairment will be considered if any of the following: muscle tone changes, impaired fine or gross motor coordination, Bayley scale score between 71-84, moderate behaviour disorders or mild visual disability.
Time Frame
24 months
Title
Degree of neurodevelopment at 24 months corrected age
Description
Moderate impairment will be diagnosed when suffering from any of the following: spastic diplegia, hemiplegia, seizures (non-febrile), Bayley scores between 50-70, severe behaviour disorders, moderate visual disability or mild-moderate hypoacusis.
Time Frame
24 months
Title
Degree of neurodevelopment at 24 months corrected age
Description
Severe impairment will be attributed to subjects with any of the following: spastic quadriplegia, choreoathetosis, ataxia, Bayley score <50, blindness or severe hypoacusis
Time Frame
24 months
Title
Degree of neurodevelopment at 6 years of age
Description
Wechsler Intelligence Scale for Children - Fifth edition. Ranges from below 69 to above 130. Scores from 90-109 indicate average, above it indicates above average and below, below average performance.
Time Frame
6 years
Title
Degree of neurodevelopment at 6 years of age
Description
Child behaviour checklist 6-18 years of age. 113 items about behaviour and social competence scored from 0 "absent" to 2 "occurs often"
Time Frame
6 years
Title
Degree of neurodevelopment at 6 years of age
Description
Behavior Rating Inventory of Executive Function, Second Edition (BRIEF2). Parent/teacher self reporting form.
Time Frame
6 years
Title
Neuroplasticity biomarkers and intestinal permeability
Description
NeuN, Doublecortin, GFAP, GDNF, Ki67, Nrf2, BDNF, NGF, neurotrophin-1 (NT-1), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), DYRK1A, HIF1α, S100B i GSK3B. IL1B, IL6, IL8, IL10, IL12, TNF- α
Time Frame
6 years
Secondary Outcome Measure Information:
Title
Incidence of necrotising enterocolitis
Description
cases fulfilling the stage II or above of the modified Bell's Criteria
Time Frame
40 weeks
Title
Mortality
Description
Proportion of dead participants before discharge
Time Frame
40 weeks
Title
Incidence of late onset sepsis
Description
positive blood culture beyond 72 hours of life
Time Frame
40 weeks
Title
Incidence of Intraventricular haemorrhage
Description
Grade I-IV
Time Frame
40 weeks
Title
Intensive care length of stay
Description
Days of intensive care
Time Frame
40 weeks

10. Eligibility

Sex
All
Maximum Age & Unit of Time
32 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Premature infants under 32 weeks gestational age and less than 1500g birthweight. Born at BCNatal Hospital Clínic between years 2014-2019. Exclusion Criteria: All neonates presenting with suspected congenital anomalies, inborn errors of metabolism, or genetic defects were excluded. Infants with a suspected syndrome, or who have suffered events beyond the neonatal period, not related to prematurity, that could entail impairment in neurodevelopment (severe cranioencephalic trauma, oncological process, meningitis, or exposure to toxic substances)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benjamin James Baucells, MD
Organizational Affiliation
Neonataology Service, BCNatal Hospital Clínic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Giorgia Sebastiani
Organizational Affiliation
Neonatology Service, BCNatal Hospital Clínic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neonataology Service, BCNatal Hospital Clinic Seu Maternitat
City
Barcelona
ZIP/Postal Code
08028
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
19220322
Citation
Sjogren YM, Jenmalm MC, Bottcher MF, Bjorksten B, Sverremark-Ekstrom E. Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin Exp Allergy. 2009 Apr;39(4):518-26. doi: 10.1111/j.1365-2222.2008.03156.x. Epub 2009 Feb 9.
Results Reference
background
PubMed Identifier
31924688
Citation
O'Reilly H, Johnson S, Ni Y, Wolke D, Marlow N. Neuropsychological Outcomes at 19 Years of Age Following Extremely Preterm Birth. Pediatrics. 2020 Feb;145(2):e20192087. doi: 10.1542/peds.2019-2087. Epub 2020 Jan 10.
Results Reference
background
Citation
Food and Agricultural Organization of the United Nations and World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. World Health Organization, (2001).
Results Reference
result
PubMed Identifier
32727119
Citation
Navarro-Tapia E, Sebastiani G, Sailer S, Toledano LA, Serra-Delgado M, Garcia-Algar O, Andreu-Fernandez V. Probiotic Supplementation During the Perinatal and Infant Period: Effects on Gut Dysbiosis and Disease. Nutrients. 2020 Jul 27;12(8):2243. doi: 10.3390/nu12082243.
Results Reference
result
PubMed Identifier
21674011
Citation
Mai V, Young CM, Ukhanova M, Wang X, Sun Y, Casella G, Theriaque D, Li N, Sharma R, Hudak M, Neu J. Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS One. 2011;6(6):e20647. doi: 10.1371/journal.pone.0020647. Epub 2011 Jun 6.
Results Reference
result
PubMed Identifier
28477669
Citation
Underwood MA, Sohn K. The Microbiota of the Extremely Preterm Infant. Clin Perinatol. 2017 Jun;44(2):407-427. doi: 10.1016/j.clp.2017.01.005. Epub 2017 Mar 22.
Results Reference
result
PubMed Identifier
28471478
Citation
Thomas JP, Raine T, Reddy S, Belteki G. Probiotics for the prevention of necrotising enterocolitis in very low-birth-weight infants: a meta-analysis and systematic review. Acta Paediatr. 2017 Nov;106(11):1729-1741. doi: 10.1111/apa.13902. Epub 2017 Jun 9.
Results Reference
result
PubMed Identifier
26611880
Citation
Baucells BJ, Mercadal Hally M, Alvarez Sanchez AT, Figueras Aloy J. [Probiotic associations in the prevention of necrotising enterocolitis and the reduction of late-onset sepsis and neonatal mortality in preterm infants under 1,500g: A systematic review]. An Pediatr (Barc). 2016 Nov;85(5):247-255. doi: 10.1016/j.anpedi.2015.07.038. Epub 2015 Nov 21. Spanish.
Results Reference
result
PubMed Identifier
31593123
Citation
Bi LW, Yan BL, Yang QY, Li MM, Cui HL. Which is the best probiotic treatment strategy to prevent the necrotizing enterocolitis in premature infants: A network meta-analysis revealing the efficacy and safety. Medicine (Baltimore). 2019 Oct;98(41):e17521. doi: 10.1097/MD.0000000000017521.
Results Reference
result
PubMed Identifier
32332478
Citation
van den Akker CHP, van Goudoever JB, Shamir R, Domellof M, Embleton ND, Hojsak I, Lapillonne A, Mihatsch WA, Berni Canani R, Bronsky J, Campoy C, Fewtrell MS, Fidler Mis N, Guarino A, Hulst JM, Indrio F, Kolacek S, Orel R, Vandenplas Y, Weizman Z, Szajewska H. Probiotics and Preterm Infants: A Position Paper by the European Society for Paediatric Gastroenterology Hepatology and Nutrition Committee on Nutrition and the European Society for Paediatric Gastroenterology Hepatology and Nutrition Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2020 May;70(5):664-680. doi: 10.1097/MPG.0000000000002655.
Results Reference
result
PubMed Identifier
21412889
Citation
Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD005496. doi: 10.1002/14651858.CD005496.pub3.
Results Reference
result
PubMed Identifier
10933736
Citation
Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N Engl J Med. 2000 Aug 10;343(6):378-84. doi: 10.1056/NEJM200008103430601.
Results Reference
result
PubMed Identifier
31404162
Citation
Hortensius LM, van Elburg RM, Nijboer CH, Benders MJNL, de Theije CGM. Postnatal Nutrition to Improve Brain Development in the Preterm Infant: A Systematic Review From Bench to Bedside. Front Physiol. 2019 Jul 26;10:961. doi: 10.3389/fphys.2019.00961. eCollection 2019.
Results Reference
result
PubMed Identifier
21303428
Citation
Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011 Mar;23(3):187-92. doi: 10.1111/j.1365-2982.2010.01664.x.
Results Reference
result
PubMed Identifier
26657483
Citation
Yang I, Corwin EJ, Brennan PA, Jordan S, Murphy JR, Dunlop A. The Infant Microbiome: Implications for Infant Health and Neurocognitive Development. Nurs Res. 2016 Jan-Feb;65(1):76-88. doi: 10.1097/NNR.0000000000000133.
Results Reference
result
PubMed Identifier
11520916
Citation
Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677-736. doi: 10.1146/annurev.neuro.24.1.677.
Results Reference
result
PubMed Identifier
31341569
Citation
Ranuh R, Athiyyah AF, Darma A, Risky VP, Riawan W, Surono IS, Sudarmo SM. Effect of the probiotic Lactobacillus plantarum IS-10506 on BDNF and 5HT stimulation: role of intestinal microbiota on the gut-brain axis. Iran J Microbiol. 2019 Apr;11(2):145-150.
Results Reference
result
PubMed Identifier
17308169
Citation
Nikolaou KE, Malamitsi-Puchner A, Boutsikou T, Economou E, Boutsikou M, Puchner KP, Baka S, Hassiakos D. The varying patterns of neurotrophin changes in the perinatal period. Ann N Y Acad Sci. 2006 Dec;1092:426-33. doi: 10.1196/annals.1365.041.
Results Reference
result
PubMed Identifier
25354496
Citation
Liu DY, Shen XM, Yuan FF, Guo OY, Zhong Y, Chen JG, Zhu LQ, Wu J. The Physiology of BDNF and Its Relationship with ADHD. Mol Neurobiol. 2015 Dec;52(3):1467-1476. doi: 10.1007/s12035-014-8956-6. Epub 2014 Oct 30.
Results Reference
result
PubMed Identifier
29637171
Citation
Jacobs SE, Hickey L, Donath S, Opie GF, Anderson PJ, Garland SM, Cheong JLY; ProPremsStudy Groups. Probiotics, prematurity and neurodevelopment: follow-up of a randomised trial. BMJ Paediatr Open. 2017 Nov 25;1(1):e000176. doi: 10.1136/bmjpo-2017-000176. eCollection 2017.
Results Reference
result
PubMed Identifier
19914635
Citation
Chou IC, Kuo HT, Chang JS, Wu SF, Chiu HY, Su BH, Lin HC. Lack of effects of oral probiotics on growth and neurodevelopmental outcomes in preterm very low birth weight infants. J Pediatr. 2010 Mar;156(3):393-6. doi: 10.1016/j.jpeds.2009.09.051. Epub 2009 Nov 14.
Results Reference
result
PubMed Identifier
20410904
Citation
Romeo MG, Romeo DM, Trovato L, Oliveri S, Palermo F, Cota F, Betta P. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol. 2011 Jan;31(1):63-9. doi: 10.1038/jp.2010.57. Epub 2010 Apr 22.
Results Reference
result
PubMed Identifier
22566113
Citation
Sari FN, Eras Z, Dizdar EA, Erdeve O, Oguz SS, Uras N, Dilmen U. Do oral probiotics affect growth and neurodevelopmental outcomes in very low-birth-weight preterm infants? Am J Perinatol. 2012 Sep;29(8):579-86. doi: 10.1055/s-0032-1311981. Epub 2012 May 7.
Results Reference
result
PubMed Identifier
20431465
Citation
Johnson S, Hollis C, Kochhar P, Hennessy E, Wolke D, Marlow N. Psychiatric disorders in extremely preterm children: longitudinal finding at age 11 years in the EPICure study. J Am Acad Child Adolesc Psychiatry. 2010 May;49(5):453-63.e1.
Results Reference
result

Learn more about this trial

Probiotics and the Neurodevelopment in the Premature Infant <32 Weeks Gestational Age and <1500g

We'll reach out to this number within 24 hrs